Guardant Health has entered into a definitive agreement to acquire Bellwether Bio. The transaction is expected to close in April. The Bellwether Bio team will join Guardant Health to further advance its early detection product pipeline. At the AACR annual meeting, investigators from Guardant Health and the Samsung Medical Center will report results from a pilot study of Guardant’s LUNAR assay in early stage cancer. The study demonstrates that addition of epigenomics to the assay can potentially lead to significant improvements in sensitivity for stage I and II colorectal cancer.
https://thefly.com/landingPageNews.php?id=2884935
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.